February 23rd 2021
By Tony Hagen
Although a more costly medicine, obinutuzumab proved more cost-effective over the long run than rituximab biosimilars in follicular lymphoma.
February 22nd 2021
Gary H. Lyman, MD, PhD, provides an expert overview on overcoming the challenges of discussing biosimilars with patients.
February 15th 2021
Patient characteristics are predictive of whether a switch to a biosimilar is likely to be accepted, investigators found.
February 9th 2021
Biosimilar competition took a big chunk of revenue from Roche's aging blockbusters in 2020, and the company is banking on its newer medicines to drive fresh revenue growth.
February 8th 2021
Physician specialty and practice setting each play a significant role in whether biosimilars are administered vs originators, according to a large, cross-sectional study.
February 4th 2021
Amgen described how a double-edged biosimilars sword has worked for and against the company's profit margin.
February 3rd 2021
Pfizer's investment in biosimilars is starting to pay off, as it now ranks these agents among its top revenue drivers.
February 2nd 2021
By Skylar Jeremias
Findings from biosimilar studies of Kanjinti (trastuzumab) and Mvasi and Zirabev (bevacizumab) rounded out our oncology biosimilar coverage in January.
February 1st 2021
The pharmacy benefit manager reported 90% biosimilar uptake among its health plans that adopted clinical management policies that included step therapy or parity usage.
January 30th 2021
By Deana Ferreri, PhD
Investigators noted comparable use of bevacizumab biosimilar and reference products among patients treated for metastatic colorectal cancer (mCRC).
